Metalloenzyme inhibitor compounds

1. A compound having the formula:

or an ester prodrug thereof.

2. A method of treating a subject suffering from or susceptible to a fungal infection by administering an effective amount of the compound of claim 1 to a subject in need thereof.

3. The method of claim 2 , wherein the fungal infection is associated with one or more of the following pathogenic fungi: Absidia corymbifera, Ajellomyces dermatitidis, Arthroderma benhamiae, Arthroderma fulvum, Arthroderma gypseum, Arthroderma incurvaturn, Arthroderma otae, Arthroderma vanbreuseghemii, Aspergillus flavus, Aspergillus fumigates, Aspergillus niger, Blastomyces dermatitidis, Candida albicans, Candida glabrata, Candida guilliermondii, Candida krusei, Candida parapsilosis, Candida tropicalis, Candida pelliculosa, Cladophialophora carrionii, Coccidioides immitis, Cryptococcus neoformans , Cunninghamella sp., Epidermophyton floccosum, Exophiala dermatitidis, Filobasidiella neoformans, Fonsecaea pedrosoi, Fusarium solani, Geotrichum candidum, Histoplasma capsulaturn, Hortaea werneckii, Issatschenkia orientalis, Madurella grisae, Malassezia fur fur, Malassezia globosa, Malassezia obtusa, Malassezia pachydermatis, Malassezia restricta, Malassezia slooffiae, Malassezia sympodialis, Microsporum canis, Microsporum flavum, Microsporum gypseum, Mucor circinelloides, Nectria haematococca, Paecilomyces variotii, Paracoccidioides brasiliensis, Penicillium marneffei, Pichia anomala, Pichia guilliermondii, Pneumocystis carinii, Pseudallescheria boydii, Rhizopus oryzae, Rhodotorula rubra, Scedosporium apiospernium, Schizophyllum commune, Sporothrix schenckii, Trichophyton mentagrophytes, Trichophyton rubrum, Trichophyton verrucosum, Trichophyton violaceum, Trichosporon asahii, Trichosporon cutaneum, Trichosporon inkin, Trichosporon mucoides.

4. The method of claim 2 , wherein the fungal infection is Aspergillosis, Blastomycosis, Candidiasis, Chromomycosis, Coccidioidomycosis, Cryptococcosis, Dermatophytoses, Histoplasmosis, Keratomycosis, Lobomycosis, Malassezia infection, Mucormycosis, Paracoccidioidomycosis, Penicillium marneffei infection, Phaeohyphomycosis, Pneumocyctis pneumonia, or Rhinosporidiosis.

5. The method of claim 2 , wherein the fungal infection is Chagas disease (Genus Trypanosoma ), African trypanosomiasis (Genus Trypanosoma ), leishmaniasis (Genus Leishmania ), tuberculosis (Genus Mycobacterium ), leprosy (Genus Mycobacterium ), malaria (Genus Plasmodium ), or tinea (capitis, corporis, pedis, tonsurans, versicolor ).

6. The method of claim 2 , where in the fungal infection is systemic fungal infection, Onychomycosis, Coccidioidomycosis, or Cryptococcosis.

7. The method of claim 2 , wherein the subject a human.

8. The method of claim 2 , wherein the subject is an animal other than a human.

9. A compound having the formula:

or an ester prodrug thereof.

10. A method of treating a subject suffering from or susceptible to a fungal infection by administering an effective amount of the compound of claim 9 to a subject in need thereof.

11. The method of claim 2 , wherein the fungal infection is associated with one or more of the following pathogenic fungi: Absidia corymbifera, Ajellomyces dermatitidis, Arthroderma benhamiae, Arthroderma fulvum, Arthroderma gypseum, Arthroderma incurvaturn, Arthroderma otae, Arthroderma vanbreuseghemii, Aspergillus flavus, Aspergillus fumigates, Aspergillus niger, Blastomyces dermatitidis, Candida albicans, Candida glabrata, Candida guilliermondii, Candida krusei, Candida parapsilosis, Candida tropicalis, Candida pelliculosa, Cladophialophora carrionii, Coccidioides immitis, Cryptococcus neoformans , Cunninghamella sp., Epidermophyton floccosum, Exophiala dermatitidis, Filobasidiella neoformans, Fonsecaea pedrosoi, Fusarium solani, Geotrichum candidum, Histoplasma capsulaturn, Hortaea werneckii, Issatschenkia orientalis, Madurella grisae, Malassezia fur fur, Malassezia globosa, Malassezia obtusa, Malassezia pachydermatis, Malassezia restricta, Malassezia slooffiae, Malassezia sympodialis, Microsporum canis, Microsporum fulvum, Microsporum gypseum, Mucor circinelloides, Nectria haematococca, Paecilomyces variotii, Paracoccidioides brasiliensis, Penicillium marneffei, Pichia anomala, Pichia guilliermondii, Pneumocystis carinii, Pseudallescheria boydii, Rhizopus oryzae, Rhodotorula rubra, Scedosporium apiospernium, Schizophyllum commune, Sporothrix schenckii, Trichophyton mentagrophytes, Trichophyton rubrum, Trichophyton verrucosum, Trichophyton violaceum, Trichosporon asahii, Trichosporon cutaneum, Trichosporon inkin, Trichosporon mucoides.

12. The method of claim 2 , wherein the fungal infection is Aspergillosis, Blastomycosis, Candidiasis, Chromomycosis, Coccidioidomycosis, Cryptococcosis, Dermatophytoses, Histoplasmosis, Keratomycosis, Lobomycosis, Malassezia infection, Mucormycosis, Paracoccidioidomycosis, Penicillium marneffei infection, Phaeohyphomycosis, Pneumocyctis pneumonia, or Rhinosporidiosis.

13. The method of claim 9 , wherein the fungal infection is Chagas disease (Genus Trypanosoma ), African trypanosomiasis (Genus Trypanosoma ), leishmaniasis (Genus Leishmania ), tuberculosis (Genus Mycobacterium ), leprosy (Genus Mycobacterium ), malaria (Genus Plasmodium ), or tinea (capitis, corporis, pedis, tonsurans, versicolor ).

14. The method of claim 9 , where in the fungal infection is systemic fungal infection, Onychomycosis, Coccidioidomycosis, or Cryptococcosis.

15. The method of claim 9 , wherein the subject a human.

16. The method of claim 9 , wherein the subject is an animal other than a human.

17. A compound (S)-4-((4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)ethynyl)phenoxy)methyl)benzonitrile.

18. A method of treating a subject suffering from or susceptible to a fungal infection by administering an effective amount of the compound of claim 17 to a subject in need thereof.

19. The method of claim 18 , where in the fungal infection is systemic fungal infection, Onychomycosis, Coccidioidomycosis, or Cryptococcosis.